Deutsche Bank AG Sells 111,861 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

Deutsche Bank AG lessened its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 24.2% during the 4th quarter, HoldingsChannel reports. The firm owned 350,614 shares of the company’s stock after selling 111,861 shares during the period. Deutsche Bank AG’s holdings in Stoke Therapeutics were worth $3,867,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Baker BROS. Advisors LP increased its position in Stoke Therapeutics by 6.1% in the fourth quarter. Baker BROS. Advisors LP now owns 4,633,838 shares of the company’s stock worth $51,111,000 after purchasing an additional 265,395 shares during the last quarter. Geode Capital Management LLC increased its position in Stoke Therapeutics by 0.7% during the fourth quarter. Geode Capital Management LLC now owns 877,095 shares of the company’s stock valued at $9,677,000 after acquiring an additional 6,264 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Stoke Therapeutics by 103.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 538,900 shares of the company’s stock valued at $5,943,000 after acquiring an additional 273,890 shares during the last quarter. Northern Trust Corp increased its position in Stoke Therapeutics by 3.4% during the fourth quarter. Northern Trust Corp now owns 350,788 shares of the company’s stock valued at $3,869,000 after acquiring an additional 11,635 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in Stoke Therapeutics by 8.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 342,129 shares of the company’s stock valued at $3,774,000 after acquiring an additional 25,995 shares during the last quarter.

Stoke Therapeutics Trading Up 0.7%

NASDAQ STOK opened at $9.83 on Tuesday. The company’s 50-day moving average price is $8.18 and its 200-day moving average price is $9.92. The stock has a market cap of $536.69 million, a PE ratio of -4.68 and a beta of 1.20. Stoke Therapeutics, Inc. has a 12 month low of $5.35 and a 12 month high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.38. The firm had revenue of $22.61 million for the quarter, compared to analysts’ expectations of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. As a group, sell-side analysts forecast that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current year.

Insider Transactions at Stoke Therapeutics

In other news, insider Barry Ticho sold 3,884 shares of the company’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the transaction, the insider now directly owns 63,962 shares in the company, valued at approximately $554,550.54. This represents a 5.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the transaction, the director now owns 148,253 shares in the company, valued at approximately $1,285,353.51. The trade was a 6.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 16,532 shares of company stock worth $143,332. Insiders own 11.30% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on STOK shares. Chardan Capital reiterated a “buy” rating and set a $24.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. HC Wainwright cut their price objective on shares of Stoke Therapeutics from $47.00 to $35.00 and set a “buy” rating on the stock in a research report on Wednesday, May 14th. Cantor Fitzgerald upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a research report on Wednesday, May 14th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, April 9th. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $23.20.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.